Opendata, web and dolomites

ZENEO

ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZENEO project word cloud

Explore the words cloud of the ZENEO project. It provides you a very rough idea of what is the project "ZENEO" about.

suddenly    needle    crossject    seventeen    allergies    14    injection    total    line    generate    minutes    roi    avoiding    estimate    close    anaphylactic    airways    situations    huge    q4    administer    enter    136m    big    launch    happen    right    innovative    food    quick    performs    young    intramuscular    prone    patients    adrenaline    revenues    discomfort    reactions    zeneo    someone    turnover    payback    adults    room    causes    filled    worldwide    europeans    counteract    suitable    serious    shock    plan    sends    life    threatening    aged    company    reaction    relatives    create    allergic    emergency    autoinjectors    allergy    anaphylaxis    prefilled    billion    fifth    last    free    2021    profit    syringes    death    heart    suffer    oxygen    injector    anyone    guarantee    player    device    hospitalizations    million    commercialization    reg    risk    124m    auto    inject    jobs    edge    solution    market    28    children    properly    contamination    36    cutting    guarantees    people   

Project "ZENEO" data sheet

The following table provides information about the project.

Coordinator
CROSSJECT 

Organization address
address: 6 RUE PAULINE KERGOMARD ZAC PARC MAZEN SULLY
city: DIJON
postcode: 21000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.crossject.com/en
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CROSSJECT FR (DIJON) coordinator 50˙000.00

Map

 Project objective

Anaphylactic shock is a serious, life-threatening allergic reaction in which the airways suddenly close; if not properly treated it causes death in 20 minutes. Seventeen million Europeans suffer from food allergies, 3.5 million which are children or young adults. Across Europe, food allergy is the leading cause of anaphylaxis in children aged 0-14 years and there is a huge increase in hospitalizations for allergic reactions in children in the last 10 years. Anaphylaxis sends someone to the emergency room every 3 minutes. The only way to counteract an anaphylactic shock is to inject adrenaline to guarantee enough oxygen to the heart. The adrenaline market is estimated to create revenues of €1.2 billion worldwide, and there is only one big player that produce prefilled syringes. Crossject already has the know-how to produce pre-filled needle free autoinjectors, our ZENEO® line. We already have 4 ZENEO® products so we are the right company to enter the adrenaline market with a cutting-edge solution. ZENEO® Adrenaline is an innovative, needle-free, easy-to-use auto-injector suitable for emergency situations, that enables patients and relatives to administer adrenaline. It performs a quick injection (1/10 of a second) avoiding the needle-related discomfort and the risk of contamination, moreover it guarantees intramuscular injection. The end-users of our product are people that are having an anaphylactic shock. People with food allergies are those that will need our device the most as they are more prone to anaphylaxis, however an anaphylactic shock can happen to anyone. We plan to launch ZENEO® Adrenaline on the market in Q4 2021. We will a turnover of €136M and a profit of €124M by the fifth year of commercialization. We expect to achieve the payback between the second and the third year of commercialization and to generate ROI of 3.36 by the fifth year of commercialization. Moreover, we estimate to create a total of 28 new jobs during these 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZENEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZENEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More